DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT00569907

Completed

Observational Study of Interstitial Glucose Monitoring With Continuous Glucose Monitoring to Track Patients Treated With Exenatide

Asset

Exenatide

GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

18

actual

Study population

Type 2 diabetes

Key I/E criterion

•HbA1c 7.1-11%

Primary endpoint

—

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00569907
Org study ID03520-06-C

Timeline

Milestones

Study first posted2007-12-10estimated
Last update posted2015-11-26estimated
Study start2007-01 (month precision)
Primary completion2009-05actual (month precision)
Study completion2009-05actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age21 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Community sample.

Inclusion criteria

•Male or female (if of child-bearing age must practice appropriate birth control such as tubal ligation, oral contraceptives, abstinence or vasectomized partner during the duration of the study)
•Previously diagnosed with type 2 diabetes
•Age 21 and older
•Treated with metformin, a sulfonylurea, a thiazolidinedione, a combination or metformin and a sulfonylurea, or a combination of metformin and a thiazolidinedione (approved FDA indications)
•HbA1c 7.1-11%, unless subject has been using exenatide prior to study; in that case, there is no restriction on HbA1c level.
•Willing to give informed consent
•Motivated and capable of following the protocol and instructions provided by the healthcare professional
•Available for the study on the scheduled visit days
•Access to telephone communications

Exclusion criteria

•Under 21 years of age
•Pregnancy
•Creatinine clearance <30 ml/min (using MDRD formula)
•Known gastrointestinal disease
•Without diabetes or known type 1 diabetes
•Unable to follow the study protocol
•Unable to read and write in English
•Allergy to adhesives
•Any concomitant medical condition that would likely affect the evaluation of CGM device performance as determined by the investigator such as dermatological conditions or myxedema.

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Publications (4)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.